Alice Chen, Ph.D.

Over 20 years of experience in the US pharmaceutical/biotech industry with a successful track record in drug discovery and translational research.

Served as a Research Fellow at 23andMe Inc., built up a biology team and led 23andMe’s internal and joint drug discovery effort with GSK in the oncology area; Under her leadership, a portfolio of immuno-oncology drug candidates has successfully advanced in 5 years, including 23andMe’s first and second compounds entering clinical trials; Led a biology team at NGM Bio-pharmaceuticals in California and discovered two compounds that entered into pre-clinical development; During her tenure at the Genomics Institute of the Novartis Research Foundation (GNF) in California, she led biology platforms and discovery projects, and made a significant contribution to the discovery of Siponimod, an approved drug for relapsing-remitting and secondary progressive multiple sclerosis.

Ph.D. in Neuroscience from Stanford University, BS in Biology from California Institute of Technology.

Published more than 20 scientific research papers with first-authored publications in prestigious journals such as Nature and Cell.